NVAX

Novavax

October 5, 2026 · intraday

Rarity

3.37

Peak move

+27.44%

Float cap

$1.6B

Novavax is a Gaithersburg, Maryland-based vaccine company that develops recombinant protein-based nanoparticle vaccines and its proprietary Matrix-M adjuvant. It sells its protein-based, non-mRNA COVID-19 vaccine, Nuvaxovid, to governments and health systems, and licenses its technology to partners such as Sanofi, Takeda and the Serum Institute of India, which uses Matrix-M in its malaria vaccine. Its pipeline spans seasonal influenza, COVID-influenza combinations, RSV and other infectious-disease candidates.

• major_contractOct 3

  Novavax's Matrix-M adjuvant has been licensed by four of the world's ten largest pharmaceutical companies, including Pfizer's up-to-$500M milestone deal, which management frames as validation of its shift from COVID vaccine maker to platform licensor.

  Webeeo.com.cnWebeeo.com.cn
• regulatory_approvalOct 2 · 11:35 ET

  The US FDA approved updated 2026-2027 COVID-19 vaccine formulations targeting the JN.1-lineage XFG variant, including Novavax partner Sanofi's protein-based Nuvaxovid for adults 65+ and people 12-64 at high risk, plus Pfizer/BioNTech's Comirnaty and Moderna's Spikevax and mNEXSPIKE.

  Webdnevnik.rs